- Home
- KFS vs GOSS Comparison
KFS vs GOSS Comparison
Compare KFS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- GOSS
- Stock Information
- Founded
- KFS 1989
- GOSS 2015
- Country
- KFS United States
- GOSS United States
- Employees
- KFS N/A
- GOSS N/A
- Industry
- KFS Property-Casualty Insurers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- GOSS Health Care
- Exchange
- KFS Nasdaq
- GOSS Nasdaq
- Market Cap
- KFS 396.0M
- GOSS 347.8M
- IPO Year
- KFS 1996
- GOSS 2019
- Fundamental
- Price
- KFS $14.37
- GOSS $2.47
- Analyst Decision
- KFS
- GOSS Strong Buy
- Analyst Count
- KFS 0
- GOSS 4
- Target Price
- KFS N/A
- GOSS $8.50
- AVG Volume (30 Days)
- KFS 68.0K
- GOSS 3.1M
- Earning Date
- KFS 08-07-2025
- GOSS 08-05-2025
- Dividend Yield
- KFS N/A
- GOSS N/A
- EPS Growth
- KFS N/A
- GOSS N/A
- EPS
- KFS N/A
- GOSS N/A
- Revenue
- KFS $119,287,000.00
- GOSS $40,237,000.00
- Revenue This Year
- KFS N/A
- GOSS N/A
- Revenue Next Year
- KFS N/A
- GOSS $30.65
- P/E Ratio
- KFS N/A
- GOSS N/A
- Revenue Growth
- KFS 12.05
- GOSS N/A
- 52 Week Low
- KFS $7.06
- GOSS $0.66
- 52 Week High
- KFS $16.80
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- KFS 54.71
- GOSS 68.08
- Support Level
- KFS $13.96
- GOSS $2.38
- Resistance Level
- KFS $14.36
- GOSS $2.65
- Average True Range (ATR)
- KFS 0.38
- GOSS 0.15
- MACD
- KFS 0.05
- GOSS 0.03
- Stochastic Oscillator
- KFS 89.60
- GOSS 76.67
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.